Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Abstract

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmunemediated platelet destruction and impairment of platelet production. Thromboembolic events have been reported in up to 8% of patients with ITP, suggesting that thromboembolism requires special precaution in this patient group. Thromboembolism can be caused by a disease (i.e. pro-thrombotic disease state) after the introduction of ITP therapies such as corticosteroids, splenectomy, and thrombopoietin receptor agonists, or can occur in association with other diseases. In the care of patients with ITP, it is important to understand the risk of thromboembolism. In this article, we focus on the risk of ITP-related thromboembolism and potential prevention and management options.

COVID-19 complicated by immune thrombocytopaenic purpura and internal jugular vein thrombosis

“…Treatment should always be personalised to the individual to minimise bleeding and risk of thromboembolism. 17 For the treatment of thrombosis in patients with ITP (with no bleeding, petechiae, hematomas or stable hb (WHO grade 0-II), anticoagulation should be started at standard doses with a platelet count of ≥50 10⁹/L/ or at half-standard doses with a platelet count of <50 000/μL and increased to full doses if platelet counts rise to ≥50 000/μL. 18 There have been multiple reports in the literature highlighting the thrombotic manifestations of COVID-19, including venous thromboembolic disease and arterial thrombosis.…”

Treatment tactics for acute coronary syndrome in primary immune thrombocytopenia

“…Развитие тромботических процессов у больных ПИТ стало предметом специальных исследований и породило концепцию «тромбоцитопенической тромбофилии», озвученной в специальной статье под названием: «Является ли иммунная тромбоцитопения (ИТП) тромбофилией?» [3]. По данным метаанализа нескольких исследований, у больных ПИТ выявлен высокий риск артериальных и венозных тромбозов по сравнению с показателями в популяции [4][5][6][7][8][9].…”